ライフサイエンスコーパス: clonal hematopoiesis

1 progenitor cells (HSPCs) and/or by promoting clonal hematopoiesis.

2 isorders in which recurrent mutations define clonal hematopoiesis.

3 ts with congenital neutropenia to assess for clonal hematopoiesis.

4 ion or chromosomal abnormality indicative of clonal hematopoiesis.

5 -forming unit colonies but not in those with clonal hematopoiesis.

6 eoplasms (MPN) characterized by multilineage clonal hematopoiesis.

7 polyclonal hematopoiesis and in 4 of 10 with clonal hematopoiesis.

8 tion not only to MPN, but also to JAK2 V617F clonal hematopoiesis, a more common phenomenon that may

9 that define myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation, peripher

10 matopoiesis at the time of ABMT or developed clonal hematopoiesis after ABMT.

11 In 3 patients with clonal hematopoiesis analyzed by WES, we identified a so

12 (PMF) are chronic diseases characterized by clonal hematopoiesis and hyperproliferation of terminall

13 s and have a propensity for the evolution to clonal hematopoiesis and malignancy.

14 omising way to model the complex genetics of clonal hematopoiesis and myeloid disorders using CRISPR-

15 deficient mice to generate genetic models of clonal hematopoiesis and neoplasia.

16 r disease-modifying drugs that can eradicate clonal hematopoiesis and/or prevent progression to more

17 Lynch syndrome, clonal hematopoiesis, and cervical intraepithelial neopl

18 ol, which was termed in the past age-related clonal hematopoiesis (ARCH).

19 l hematopoiesis at the time of ABMT and that clonal hematopoiesis, as detected by the HUMARA assay, i

20 Our findings support the occurrence of clonal hematopoiesis-associated mutations as a widesprea

21 at a significant proportion of patients have clonal hematopoiesis at the time of ABMT and that clonal

22 skewed XIP, and 10 of 78 (13.5%) either had clonal hematopoiesis at the time of ABMT or developed cl

23 Age-associated clonal hematopoiesis caused by acquired mutations in mye

24 Clonal hematopoiesis (CH) arises when a substantial prop

25 Clonal hematopoiesis (CH), as evidenced by recurrent som

26 This clonal hematopoiesis correlates with an increased risk o

27 The acquisition of clonal hematopoiesis-driver mutations (CHDMs) occurs wit

28 Clonal hematopoiesis due to mutations in TP53 was presen

29 Conversely, clonal hematopoiesis due to mutations of CSF3R was prese

30 hematopoiesis, most individuals who acquire clonal hematopoiesis during aging will never develop MDS

31 lly heterogeneous disorders characterized by clonal hematopoiesis, impaired differentiation, peripher

32 We found evidence of clonal hematopoiesis in 5 of 8 studied cases based on cl

33 f TCA established the presence or absence of clonal hematopoiesis in about 90% of female subjects.

34 We did not detect clonal hematopoiesis in any of the tested subjects.

35 HUMARA alleles, was reported as evidence of clonal hematopoiesis in approximately 30% of elderly wom

36 nality assays are suitable for evaluation of clonal hematopoiesis in elderly women.

37 This HUMARA at times indicated clonal hematopoiesis in healthy elderly women, thus prec

38 mosome genes (qTCA) and found no evidence of clonal hematopoiesis in healthy nonanemic elderly person

39 Furthermore, we did not detect clonal hematopoiesis in more than 200 healthy nonelderly

40 been observed in AML and in individuals with clonal hematopoiesis in the absence of leukemic transfor

41 roliferative neoplasms (MPNs) and JAK2 V617F clonal hematopoiesis in the general population.

42 second most commonly mutated gene linked to clonal hematopoiesis, in the hematopoietic cells of athe

43 Age-related clonal hematopoiesis is a common condition that is assoc

44 The observed proportion of putatively clonal hematopoiesis is similar to the lifetime incidenc

45 ic morphology of blood and marrow cells, and clonal hematopoiesis, most individuals who acquire clona

46 ns in TET2 occur frequently in patients with clonal hematopoiesis, myelodysplastic syndrome (MDS), an

47 Clonal hematopoiesis occurs normally, especially with ag

48 Purpose Clonal hematopoiesis of indeterminate potential (CHIP) i

49 Clonal hematopoiesis of indeterminate potential (CHIP),

50 d dysplastic hematopoiesis can be considered clonal hematopoiesis of indeterminate potential (CHIP),

51 tion sequencing (NGS) discovered age-related clonal hematopoiesis of indeterminate potential (CHIP).

52 ave been characterized as frequent events in clonal hematopoiesis of indeterminate potential, suggest

53 ng individuals with idiopathic cytopenias or clonal hematopoiesis of undetermined significance, the i

54 malignancy consistent with the concept that clonal hematopoiesis precedes stem cell malignancy.

55 These patients have BCR-ABL1-positive clonal hematopoiesis resembling a chronic myeloid leukem

56 Clonal hematopoiesis results from somatic mutations in h

57 s drives disease evolution from asymptomatic clonal hematopoiesis to frank MDS, and, ultimately, to s

58 d across a phenotypic continuum ranging from clonal hematopoiesis to myelodysplastic syndrome (MDS) a

59 ancies exist on a spectrum from asymptomatic clonal hematopoiesis to overt leukemia and exhibit subst

60 ation pattern (XIP) was 20% (21/104), and of clonal hematopoiesis was 3% (3/104).

61 Clonal hematopoiesis was a strong risk factor for subseq

62 screened included 40 regions known to drive clonal hematopoiesis when mutated and 64 novel candidate

63 rom normal, healthy elderly individuals with clonal hematopoiesis who are at increased risk of subseq

64 n morphologic remission may continue to have clonal hematopoiesis with populations closely related to

65 Clonal hematopoiesis with somatic mutations is readily d

66 Clonal hematopoiesis with somatic mutations was observed

67 Assays that could reliably detect clonal hematopoiesis would therefore be extremely valuab